February 7, 2026

TRIPURA STAR NEWS

Tripura's Latest News, Views & News Portal

Medistep Healthcare Limited Gets Subscribed Nearly 356 Times At Close.

Spread the love

Gujarat, 12th of August 2025 : Medistep Healthcare Limited gets subscribed nearly 356 times at close

Total Issue Size37,44,000 shares
Bids received1,33,38,15,000 shares
No. of times issue is subscribed356.25

·       Qualified Institutional Buyers (QIBs): 2,46,63,000 shares

·       Non-Institutional Investors (NII): 48,90,18,000 shares

·       Individual Investors: 82,01,34,000 shares

IPO details:

· Total Issue: Up to 37,44,000 Equity Shares

· Face Value: ₹10/- Each

· Issue Size: ₹16.09 Crore (Fixed Price Issue)

· Issue Price: ₹43/- per share

· Lot Size: 3,000 Equity

Shares Offer Structure

· Retail Individual Investor: Not less than 17,79,000 Equity Shares

· Non-Institutional Investor: Not more than 17,76,000 Equity Shares

· Market Maker: 1,89,000 Equity Shares

IPO Timeline:

· Issue Opening Date: 8th August, 2025

· Issue Closing date: 12th August, 2025

· Listing Date: 18th August, 2025

Pre & Post Issue Equity Shares

· Pre Issue Equity Shares: 1,04,65,546

· Post Issue Equity Shares: 1,42,09,546

· Post Issue Implied Market Cap: ₹61.10 Crore

Utilization of Net Proceeds:

· Funding of capital expenditure towards purchase of plant and machineries for expansion at the existing manufacturing facility

· Working Capital requirements

· General Corporate Purpose

Issue Intermediaries:

· Lead Managers: Fast Track Finsec Private Limited

· Registrar to the Issue: Cameo Corporate Services Limited

About Medistep Healthcare Limited:

Medistep Healthcare Limited was founded in 2023 and has strategically expanded its operations by acquiring the business of M/s MG Pharma in 2024, a proprietorship concern owned by one of its promoters, Ms. Prajapati Hetalben Girdharilal and founded in July 2018. The company has carved a niche in the healthcare industry through its expertise in manufacturing sanitary pads, energy powder and trading a diverse range of pharmaceutical products, nutraceutical products, intimate products and surgical products through a vast distribution network.

The company recorded revenue from operations of Rs 4965.48 lakhs in FY25, up from Rs 3907.19 lakhs in FY24. The company’s EBITDA grew from Rs 454.2 lakh in FY24 to Rs 560 lakh in FY25. The company’s PAT grew from Rs 332.76 lakh in FY24 to Rs 414.42 lakh in FY25.

About The Author